HTB

PK and drug interactions

Higher risk of potential drug-drug interactions in HIV patients over 60

Smoking and atazanavir levels

Darunavir/ritonavir and rosuvastatin

Darunavir/ritonavir and hepatic impairment

Case report – lack of PK interaction between bosentan and nevirapine

Pharmacokinetics of once daily darunavir/ritonavir and efavirenz

11th International Workshop on Clinical Pharmacology of HIV Therapy, 7-9 April, 2010, Sorrento, Italy

Atazanavir absorption maximised with food

Methadone levels reduced moderately by rilpivirine

Maraviroc 150mg once-daily achieves target concentrations with atazanavir/ritonavir

Raltegravir and unboosted atazanavir

Raltegravir dose adjustment not required for patients on dialysis

Raltegravir and darunavir pharmacokinetics in liver disease

Tenofovir may require closer renal monitoring in older patients

Effect of age on atazanavir, darunavir, raltegravir and etravirine

Proposed approach to measuring TDM for raltegravir

Increased bilirubin levels when atazanavir is dosed twice-daily

Poor bioequivalence with crushed and dissolved tablets

No clinically relevant interactions between TMC278 and oral contraceptives (norethindrone plus ethinylestradiol)

Pilot PK study of two generic paediatric formulations of lopinavir/ritonavir vs originator products

Other selected PK and drug interaction summaries from EACS

No interaction between tipranavir/ritonavir and efavirenz

Significant interactions between tipranavir/ritonavir and statins

Summary of interactions between vivriviroc and other ARVs

Significant interaction between atazanavir/ritonavir and the antipsychotic drug quetiapine

Alcohol and marijuana may reduce drug levels of atazanavir and efavirenz

Other drug interaction studies at ICAAC

Reduced etravirine levels after direct switch from efavirenz

Gemfibrozil significantly reduced by lopinavir/r

Raltegravir trough levels reduced by etravirine may require use of TDM

Lopinavir/r affects PK exposure of some antimalarial drugs

Darunavir/r increases exposure to nevirapine

Interaction between Ginkgo biloba and efavirenz

Use of raltegravir in HIV-positive transplant recipients

Monotherapy study may explain previous poor clinical results when abacavir and tenofovir are used in combination

Interactions between ARVs and antimalarials atovaquone and proguanil

Efavirenz lowers levels of darunavir given as 900/100mg once daily with ritonavir

Potential interactions between antiviral treatment for swine flu (H1N1) and anti-HIV therapy

Case reports of significant interactions between etravirine and raltegravir

Effect of tenofovir on abacavir phosphorylation

PI interactions: lopinavir/rifampicin, saquinavir, atazanavir/tenofovir in pregnancy

Effects of omeprazole on plasma levels of raltegravir

Interaction study of ketoconazole and ritonavir-boosted saquinavir

Tipranavir/ritonavir interactions with clarithromycin, fluconazole and rifabutin

Antiretroviral and statin drug-drug interactions

Elvitegravir with tipranavir/ritonavir or darunavir/ritonavir

Serum bilirubin increases when PEG-interferon and ribavirin are used with atazanavir

Drug interactions with integrase inhibitors

Drug interactions between efavirenz and itraconazole

Effect on tacrolimus when switching from nelfinavir to fosamprenavir

Drug interaction studies with approved drugs

Key papers on methadone and ritonavir

Drug interaction reports from Liverpool University website

Darunavir/ritonavir interaction with clarithromycin warrants caution

Updated and new resources on HIV drug interactions

Drug interaction studies presented at EACS

New drug interaction summary tables: maraviroc, integrase inhibitors, etravirine, hormonal contraceptives

Acid reducing agents and protese inhibitors

Atazanavir, with or without ritonavir, may increase buprenorphine and buprenorphine metabolites, requiring dose adjustment

T-20 increases tipranavir levels but not hepatotoxicity

The effect of lopinavir/r on the renal clearance of tenofovir

Drug-drug interactions

Drug interactions and pharmacokinetic studies: CROI 2007

Drug interactions with darunavir (TMC-114)

Drug interactions with etravirine (TMC-125)

Post navigation